Oncology

Multiple Myeloma

Expert Roundtables Podcast: The Optimal Sequencing of Novel Therapies in Relapsed/Refractory Multiple Myeloma

expert roundtables by Kenneth C. Anderson, MD; Carol Ann Huff, MD; Shaji K. Kumar, MD

CAR T-cell therapy and bispecific antibodies are now available for patients with relapsed/refractory multiple myeloma, but the optimal sequencing of these agents has not been established. Our featured experts discuss the current use of these novel therapies and the available data about their sequencing.

Profile

Kenneth C. Anderson, MD

Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA

Profile

Carol Ann Huff, MD

Associate Professor
Departments of Oncology and Medicine
Medical Director
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, MD

Profile

Shaji K. Kumar, MD

Consultant and Research Chair, Division of Hematology
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma, Amyloidosis, Dysproteinemia Group
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, MN